Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5844779 | 0.82 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL5843292 | 0.73 | CRHR1 (0.59) | CRHR1 | |
| SCHEMBL5843299 | 0.73 | LMNA (0.35) | CRHR1KMT2AMAPTMEN1LMNA | |
| SCHEMBL5844606 | 0.71 | TAAR1 (0.37) | KMT2AMEN1LMNA | |
| SCHEMBL5843102 | 0.71 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL7354022 | 0.70 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL7354028 | 0.69 | CRHR1 (0.32) | CRHR1KMT2AMEN1LMNA | |
| SCHEMBL9935610 | 0.62 | RAPGEF4 (0.43) | KMT2AMAPTMEN1LMNATSHR | |
| SCHEMBL8345724 | 0.61 | NOS3 (0.59) | MAPTLMNACYP3A4TSHR | |
| SCHEMBL12715650 | 0.60 | KDM4E (0.32) | KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125880-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7067664-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-6956047-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| EP-0764166-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER (US) | 2000-09-13 | — | — | EP | disclosed |
| US-5962479-A | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032846-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885KMT2A 3907/4885MAPT 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.